WeVote
Log In

Bill

Bill

A 2202

Relates to the use of topical pharmaceutical agents

2025 Regular Session Introduced by Marianne Buttenschon and 9 co-sponsors

Bill A 2202 regulates topical pharmaceutical agents, ensuring safe use through guidelines, training for healthcare providers, and enhanced patient safety measures.

REFERRED TO HIGHER EDUCATION
0
WeVote Research Nonpartisan
Bill Summary · A 2202

Summary of Bill A 2202: Relating to the Use of Topical Pharmaceutical Agents

Bill Overview

  • Bill Number: A 2202
  • Title: Relates to the use of topical pharmaceutical agents
  • Status: Referred to Higher Education
  • Introduced On: January 15, 2025
  • Classification: Bill

Purpose and Intent

Bill A 2202 aims to regulate and enhance the use of topical pharmaceutical agents within the healthcare system. The intent is to ensure that these agents are utilized safely and effectively, providing clear guidelines for their application in various medical settings.

Key Provisions

While the specific text of the bill is not provided, typical provisions in similar legislation may include:

  • Definition of Topical Pharmaceutical Agents: Establishing a clear definition of what constitutes a topical pharmaceutical agent, including examples of commonly used products.

  • Regulatory Framework: Creating a framework for the approval, distribution, and use of these agents, potentially involving oversight by relevant health authorities or boards.

  • Training Requirements: Mandating training or certification for healthcare professionals who administer or prescribe topical agents to ensure proper usage and patient safety.

  • Patient Safety Measures: Implementing guidelines to monitor and report adverse effects associated with the use of topical agents, promoting patient safety and informed consent.

Affected Parties

The bill would primarily impact:

  • Healthcare Providers: Physicians, nurses, and pharmacists who prescribe or administer topical pharmaceutical agents would need to comply with new regulations and training requirements.

  • Patients: Individuals receiving treatment with topical agents would benefit from enhanced safety measures and informed care practices.

  • Pharmaceutical Companies: Manufacturers of topical agents may face new compliance requirements regarding the approval and marketing of their products.

Procedural Aspects

  • Current Status: As of January 15, 2025, the bill has been referred to the Higher Education committee for further consideration. This step is crucial for discussing the bill's provisions and potential amendments before it can advance to a vote.

Related Legislation

  • A 9830: A prior-session bill that may have addressed similar issues regarding pharmaceutical agents.
  • S 621: A companion bill in the Senate that likely parallels the provisions of A 2202, indicating a broader legislative interest in this area.

Conclusion

Bill A 2202 represents a significant step towards regulating the use of topical pharmaceutical agents, aiming to enhance safety and efficacy in their application. As it progresses through the legislative process, stakeholders in healthcare and pharmaceutical industries will need to stay informed about potential changes and requirements that may arise from this legislation.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.